[September 16, 2004] Biophan Technologies Names Drug Delivery Veteran John Lanzafame President of New Biophan Nanolution Division ROCHESTER, N.Y. --(Business Wire)-- Sept. 16, 2004 -- Former President of STS Biopolymers to Oversee Nanotechnology-Based Drug Delivery and Drug-Elution Medical Device Division Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, has appointed biotechnology executive John Lanzafame to serve as president of the Company's Nanolution division, according to Biophan CEO Michael Weiner. As Nanolution president, Mr. Lanzafame will oversee Biophan's development of advanced nanotechnology-based drug delivery devices and drug-elution technologies, patents, and products. Biophan estimates the market for these products and technologies at up to $40 billion. The Company will leverage its core competencies in nanoengineering, particularly its proprietary Nanoset nanomagnetic particle technology, as it develops next-generation drug delivery and drug-eluting devices. "We feel very fortunate to have someone of John Lanzafame's caliber and experience to head up Biophan's Nanolution division," said Mr. Weiner. "As one of the top professionals in the drug-delivery field, John's background will be a critical asset as we develop revolutionary nanotechnology products for this large and exciting market." Mr. Lanzafame has worked in several major aspects of the medical device industry in his 15-year career, including sales, marketing, research and development, and manufacturing. He most recently served as president of STS Biopolymers, a firm specializing in drug elution from medical device surfaces. STS Biopolymers was acquired by Angiotech Pharmaceuticals (NASDAQ: ANPI) for approximately $23 million in 2003. Angiotech is the supplier of the paclitaxel technology used on the TAXUS drug-eluting stent sold by Boston Scientific (NYSE: BSX). Further information regarding the Nanoset nanomagnetic particle technology and its applications for drug delivery is provided on the company's web site; select "Drug Delivery," either PowerPoint or HTML, at http://www.biophan.com/products.php . About Biophan Technologies Biophan Technologies develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with magnetic resonance imaging (MRI) equipment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create enhanced MRI contrast agents. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 19 issued U.S. patents and 61 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, biothermal batteries, and photonics. Biophan's technology will help realize its goal of one day making all biomedical devices capable of safely and successfully working with MRI. For more information, please visit www.biophan.com. Cautionary Statement Regarding Forward-Looking Statements Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances. [ Back To TMCnet.com's Homepage ]